Orasis's CSF-1 Eye Drop To Treat Presbyopia and Whether Cornea Is Susceptible To COVID-19 Infection

Elad Kedar, CEO (Orasis Pharmaceuticals -Herzliya, Israel)

Dr. Jonathan Miner (Washington University School of Medicine - St. Louis, MO)

Orasis Pharmaceuticals CEO Elad Kedar discusses its eye drop, CSF-1, which has undergone NEAR-1 and NEAR-2 clinical trials to treat presbyopia that adversely affects near vision as the eyes age.

Then, Dr. Jonathan Miner of the Washington University School of Medicine in St. Louis explains research into whether the cornea is suspectible to COVID-19 infection.

November 22 Podcast (Click Below)